Exclusive special offer and discount title banner vector image

ZILOSUL Osteoarthritis Drug Pipeline: 7 Major Market’s Analysis (Market Size of ZILOSUL in the 7 Major Markets for Osteoarthritis) Country Analysis (Japan, Germany, United States, France, Italy, Spain, United Kingdom)

REQUEST CUSTOMIZATION

MARKET OVERVIEW

ZILOSUL, also known as pentosan polysulfate sodium (PPS), is a semi-synthetic medication derived from the wood chips of European beech trees. The extraction process yields glucurono-xylans, which are then sulfated to create a negatively charged substance that resembles glycosaminoglycans (GAGs). GAGs are complex carbohydrates that interact with proteins involved in inflammatory processes, thereby regulating various bodily functions. 

PPS is known for its anti-inflammatory and tissue regenerative properties, along with a mild anti-thrombotic effect. Given its multiple mechanisms of action, Paradigm is investigating the potential of PPS to treat a range of conditions that originate from and are maintained by inflammation, such as osteoarthritis. This approach is particularly relevant given the increased prevalence of osteoarthritis and the demand for effective osteoarthritis treatments.

The drug is developed by Paradigm Biopharmaceuticals Limited, an Australian biopharmaceutical company dedicated to developing innovative therapies aimed at addressing unmet medical needs. The company’s focus is on the late-stage development of treatments derived from pentosan polysulfate sodium (PPS), a semi-synthetic compound with potential applications in a wide range of diseases. Paradigm’s current research pipeline includes the development of PPS-based therapies targeting inflammatory conditions, particularly respiratory disorders such as allergic rhinitis, allergic asthma, and chronic obstructive pulmonary disease.

ZILOSUL-pipeline-inkwood-research

To Know More About This Report, Request a Free Sample Copy

MARKET POTENTIAL & POSITIONING

ZILOSUL is a semi-synthetic drug formulated with pentosan polysulfate sodium (PPS), sourced from xylans of European beech trees. It is specifically designed to treat osteoarthritis by targeting the underlying disease mechanisms rather than simply alleviating symptoms. ZILOSUL supports the health of cartilage and joint tissues, which may lead to enhanced joint function and reduced pain for patients. 

Administered through subcutaneous injection, the drug is currently in Phase III clinical trials to determine its efficacy and safety in individuals with osteoarthritis. Its distinctive mechanism of action presents ZILOSUL as a promising new treatment option in the evolving field of osteoarthritis management.

In March 2023, Paradigm Biopharmaceuticals announced it had obtained parallel regulatory and ethics approvals for the pivotal PARA_OA_002 clinical trial across Belgium, Poland, and the Czech Republic. The Phase III PARA_OA_002 trial is a randomized, double-blind, placebo-controlled, multicenter study (spanning the US, Australia, the UK, the EU, and Canada) designed to assess the dosage and therapeutic effect of injectable pentosan polysulfate sodium (iPPS) in participants suffering from knee osteoarthritis pain. The application for the PARA_OA_002 trial was submitted through Europe’s newly established Clinical Trials Information System (CTIS) for evaluation in three European nations.

INKWOOD RESEARCH OFFERS AN ANALYSIS OF SEVEN KEY MARKETS

  • United States
  • Germany
  • France
  • United Kingdom
    • The UK Government has allocated approximately £69 million (~ $86 million) for research into musculoskeletal (MSK) conditions, including osteoarthritis. However, this amount is considered insufficient to adequately address the growing needs of patients suffering from these debilitating conditions. 
    • Organizations like Versus Arthritis have called on the government to increase funding for MSK research to develop more effective treatments and interventions. They argue that more substantial investment is necessary to keep pace with the rising prevalence of osteoarthritis and other related disorders, improve patient outcomes, and reduce the long-term healthcare costs associated with these conditions.
    • Moreover, the UK’s healthcare system, the NHS, is focusing on improving patient access to cutting-edge treatments and rehabilitation programs. This holistic approach, supported by ongoing investments, aims to reduce the overall burden of osteoarthritis on the healthcare system, improve patient outcomes, and enhance the quality of life for those affected.
  • Italy
  • Spain
  • Japan

TABLE OF CONTENTS

  1. INTRODUCTION TO THE REPORT
  2. ZILOSUL OVERVIEW
    1. PRODUCT DETAIL
    2. CLINICAL DEVELOPMENT
      1. CLINICAL STUDIES
      2. CLINICAL TRIALS INFORMATION
    3. OTHER DEVELOPMENTAL ACTIVITIES
    4. PRODUCT PROFILE
  3. COMPETITIVE LANDSCAPE 
    1. MARKETED THERAPIES
    2. LATE-STAGE EMERGING THERAPIES
  4. ZILOSUL MARKET ASSESSMENT
    1. MARKET OUTLOOK OF ZILOSUL IN OSTEOARTHRITIS
  5. 7 MAJOR MARKET’S ANALYSIS
    1. MARKET SIZE OF ZILOSUL IN THE 7 MAJOR MARKETS FOR OSTEOARTHRITIS
    2. 7 COUNTRY ANALYSIS
      1. MARKET SIZE OF ZILOSUL IN UNITED STATES FOR OSTEOARTHRITIS
      2. MARKET SIZE OF ZILOSUL IN GERMANY FOR OSTEOARTHRITIS
      3. MARKET SIZE OF ZILOSUL IN FRANCE FOR OSTEOARTHRITIS
      4. MARKET SIZE OF ZILOSUL IN ITALY FOR OSTEOARTHRITIS
      5. MARKET SIZE OF ZILOSUL IN SPAIN FOR OSTEOARTHRITIS
      6. MARKET SIZE OF ZILOSUL IN UNITED KINGDOM FOR OSTEOARTHRITIS
      7. MARKET SIZE OF ZILOSUL IN JAPAN FOR OSTEOARTHRITIS
  6. SWOT ANALYSIS
  7. ANALYST PERSPECTIVE

LIST OF TABLES

TABLE 1: ZILOSUL, CLINICAL TRIAL DESCRIPTION, 2024

TABLE 2: ZILOSUL, GENERAL DESCRIPTION

TABLE 3: MARKETED THERAPIES

TABLE 4: EMERGING THERAPIES

TABLE 5: ZILOSUL MARKET SIZE IN THE 7 MAJOR MARKETS, IN $ MILLION (2019–2032)

TABLE 6: ZILOSUL MARKET SIZE IN UNITED STATES, IN $ MILLION (2019–2032)

TABLE 7: ZILOSUL MARKET SIZE IN GERMANY, IN $ MILLION (2019–2032)

TABLE 8: ZILOSUL MARKET SIZE IN FRANCE, IN $ MILLION (2019–2032)

TABLE 9: ZILOSUL MARKET SIZE IN ITALY, IN $ MILLION (2019–2032)

TABLE 10: ZILOSUL MARKET SIZE IN SPAIN, IN $ MILLION (2019–2032)

TABLE 11: ZILOSUL MARKET SIZE IN UNITED KINGDOM, IN $ MILLION (2019–2032)

TABLE 12: ZILOSUL MARKET SIZE IN JAPAN, IN $ MILLION (2019–2032)

LIST OF FIGURES

FIGURE 1: ZILOSUL MARKET SIZE IN THE 7 MAJOR MARKETS, IN $ MILLION (2019–2032)

FIGURE 2: ZILOSUL MARKET SIZE IN UNITED STATES, IN $ MILLION (2019–2032)

FIGURE 3: ZILOSUL MARKET SIZE IN GERMANY, IN $ MILLION (2019–2032)

FIGURE 4: ZILOSUL MARKET SIZE IN FRANCE, IN $ MILLION (2019–2032)

FIGURE 5: ZILOSUL MARKET SIZE IN ITALY, IN $ MILLION (2019–2032)

FIGURE 6: ZILOSUL MARKET SIZE IN SPAIN, IN $ MILLION (2019–2032)

FIGURE 7: ZILOSUL MARKET SIZE IN UNITED KINGDOM, IN $ MILLION (2019–2032)

FIGURE 8: ZILOSUL MARKET SIZE IN JAPAN, IN $ MILLION (2019–2032)

FAQs

ZILOSUL is a semi-synthetic drug composed of pentosan polysulfate sodium (PPS) derived from xylans of European beech trees. It is designed for the treatment of osteoarthritis by promoting the health of cartilage and joint tissues, potentially improving joint function and reducing pain.

ZILOSUL works by mimicking glycosaminoglycans (GAGs), complex carbohydrates that interact with proteins involved in inflammation. Its mechanism of action includes anti-inflammatory properties, support for tissue regeneration, and mild anti-thrombotic effects, making it potentially effective in modifying the disease process of osteoarthritis rather than just managing symptoms.

ZILOSUL is administered via subcutaneous injection, which means it is injected under the skin. This method is chosen to ensure effective delivery of the drug to the target areas within the body.

Request Customization